Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 90 years who received a liver transplant more than 6 months ago
• People who have been diagnosed with liver cancer (HCC) that has come back after their transplant, based on specific recognised diagnostic guidelines
• People whose liver cancer has come back in an advanced form that cannot be treated with surgery or local treatments
• People who have at least one tumour that can be measured on scans and has not yet been treated
• People for whom a medical team meeting has recommended a specific combination drug treatment (atezolizumab and bevacizumab) as the first treatment option
• People whose blood counts and organ function fall within acceptable ranges on recent lab tests (taken within 14 days before starting the study), including adequate white blood cell, platelet, and red blood cell levels, healthy liver and kidney function, and normal clotting levels
• People with a physical fitness/activity level rated as 0 or 1 on a standard scale (meaning fully active or able to carry out light activity)
• People with liver function rated as Child-Pugh class A (a measure of how well the transplanted liver is working)
• Women who could become pregnant and men who agree to use effective contraception or remain abstinent during treatment and for at least 5 months after finishing atezolizumab and 6 months after finishing bevacizumab

Who may not be able to join:

• People who have had a liver rejection episode within the 3 months before starting treatment
• People whose liver biopsy shows a rejection severity score of 3 or higher before treatment begins
• People who are pregnant or breastfeeding
• People who are not enrolled in a qualifying social security or health coverage scheme (confirm with trial site — this appears to be a French regulatory requirement)
• People who have not signed a consent form for the trial
• People with a history of certain lung conditions, including idiopathic pulmonary fibrosis, organising pneumonia, drug-related lung inflammation, or unexplained lung inflammation, or who show signs of active lung inflammation on a chest scan at screening
• People who have had another cancer (other than the liver cancer in question) within the past 5 years, unless that cancer had a very low risk of spreading or causing death
• People with untreated or incompletely treated enlarged veins in the food pipe or stomach that are bleeding or at high risk of bleeding
• People who have had a bleeding episode from enlarged veins in the food pipe or stomach within the 6 months before starting the study
• People with poorly controlled high blood pressure (measured as 160 mmHg or higher systolic and/or above 100 mmHg diastolic, based on multiple readings across at least two separate occasions)
• People with a history of a severe sudden rise in blood pressure (hypertensive crisis) or blood pressure-related brain complications
• People with a history of bowel blockage or current symptoms suggesting bowel obstruction, or who need regular intravenous fluids for this reason
• People with a serious wound that is not healing, an open ulcer, or an untreated broken bone
• People whose cancer has spread to involve major airways or large blood vessels, or who have a large tumour mass in the centre of the chest
• People with a known allergy or sensitivity to atezolizumab, bevacizumab, or any of their ingredients
• People with a known allergy to products made from Chinese Hamster Ovary cells or similar laboratory-made antibody treatments
• People with a history of arterial blood clot events, including stroke, mini-stroke (TIA), or heart attack
• People who have had a significant heart or blood vessel event (such as heart attack or stroke) within the 3 months before starting the study, or who have an unstable heart rhythm or unstable chest pain
• People with protein levels in their urine exceeding 1 gram over a 24-hour collection period
• People with a history of cancer spreading to the membranes surrounding the brain and spinal cord
• People with active tuberculosis
• People who have had a serious infection within the 4 weeks before starting the study, including infections requiring hospitalisation, bacteria in the bloodstream, or severe pneumonia

Important: Always verify eligibility with the trial site directly before applying.